InvestSMART

Starpharma Holdings Limited (ASX:SPL)

ALERT: Price-sensitive ASX Announcement for SPL
Current share price for SPL : $0.685 0.345 (101.47%)+
Announcement
Release
28 Oct 2025 8:55AM
Price at Release
$0.340
Full Release
download
Summary
Starpharma Holdings Limited announced significant advancements in its strategic initiatives during Q1 FY26. The company secured a collaboration and license agreement with Genentech, providing an upfront payment of USD $5.5 million and potential milestone payments up to USD $564 million. Another agreement with Radiopharm Theranostics could yield up to AUD $89 million in milestone payments. The cash balance at the end of the quarter was $14.3 million, bolstered by a $3.7 million R&D tax incentive refund. Starpharma focuses on maximizing its DEP® platform, evidenced by these partnerships and ongoing development of its DEP® HER2 radiopharmaceuticals program, expected to enter clinical trials in 2026.
Key Points
  • Partnership with Genentech including USD $5.5 million upfront payment.
  • Agreement with Radiopharm Theranostics with potential up to AUD $89 million.
  • $3.7 million R&D tax incentive refund received.
  • Cash balance of $14.3 million at 30 September 2025.
  • Focus on DEP® platform and strategic partnerships.
  • Progression of DEP® HER2 radiopharmaceuticals program towards clinical trials.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.